DIZAL'S ZEGFROVY® (SUNVOZERTINIB) RECEIVES FDA ACCELERATED APPROVAL AS THE ONLY TARGETED ORAL TREATMENT FOR NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS

Reuters · 07/03 00:09

Please log in to view news